BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38295968)

  • 1. Risk factors for and outcomes of ring expulsions with a 1-year contraceptive vaginal system.
    Plagianos MG; Ramanadhan S; Merkatz RB; Brache V; Friedland BA; Haddad LB
    Am J Obstet Gynecol; 2024 May; 230(5):548.e1-548.e8. PubMed ID: 38295968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.
    Archer DF; Merkatz RB; Bahamondes L; Westhoff CL; Darney P; Apter D; Jensen JT; Brache V; Nelson AL; Banks E; Bártfai G; Portman DJ; Plagianos M; Dart C; Kumar N; Creasy GW; Sitruk-Ware R; Blithe DL
    Lancet Glob Health; 2019 Aug; 7(8):e1054-e1064. PubMed ID: 31231065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring.
    Stifani BM; Plagianos M; Vieira CS; Merkatz RB
    Contraception; 2018 May; 97(5):415-421. PubMed ID: 29269252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.
    Gemzell-Danielsson K; Sitruk-Ware R; Creinin MD; Thomas M; Barnhart KT; Creasy G; Sussman H; Alami M; Burke AE; Weisberg E; Fraser I; Miranda MJ; Gilliam M; Liu J; Carr BR; Plagianos M; Roberts K; Blithe D
    Contraception; 2019 Jun; 99(6):323-328. PubMed ID: 30831102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
    Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
    Weisberg E; Fraser IS; Lacarra M; Mishell DR; Jackanicz T
    Contraception; 1997 Oct; 56(4):233-9. PubMed ID: 9408704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.
    Vieira CS; Fraser IS; Plagianos MG; Burke AE; Westhoff CL; Jensen J; Brache V; Bahamondes L; Merkatz R; Sitruk-Ware R; Blithe DL
    Contraception; 2019 Dec; 100(6):438-444. PubMed ID: 31398307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraceptive vaginal ring containing segesterone acetate and ethinyl estradiol: long-acting, patient-controlled, procedure-free, reversible prescription birth control.
    Paton DM
    Drugs Today (Barc); 2019 Jul; 55(7):449-457. PubMed ID: 31347613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction.
    Merkatz RB; Plagianos M; Hoskin E; Cooney M; Hewett PC; Mensch BS
    Contraception; 2014 Nov; 90(5):514-21. PubMed ID: 24993487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis.
    Eggebroten JL; Sanders JN; Turok DK
    Am J Obstet Gynecol; 2017 Jul; 217(1):51.e1-51.e7. PubMed ID: 28342716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month expulsion of postplacental copper intrauterine devices placed after vaginal delivery.
    Gurney EP; Sonalkar S; McAllister A; Sammel MD; Schreiber CA
    Am J Obstet Gynecol; 2018 Aug; 219(2):183.e1-183.e9. PubMed ID: 29870737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users.
    Jensen JT; Archer DF; Westhoff CL; Nelson AL; Graham S; Bernick B
    J Womens Health (Larchmt); 2023 Jul; 32(7):808-815. PubMed ID: 37253139
    [No Abstract]   [Full Text] [Related]  

  • 15. A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year.
    Micks EA; Jensen JT
    Expert Opin Drug Deliv; 2020 Jun; 17(6):743-752. PubMed ID: 32410464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postplacental intrauterine device expulsion by 12 weeks: a prospective cohort study.
    Goldthwaite LM; Sheeder J; Hyer J; Tocce K; Teal SB
    Am J Obstet Gynecol; 2017 Dec; 217(6):674.e1-674.e8. PubMed ID: 28826801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation.
    Koetsawang S; Ji G; Krishna U; Cuadros A; Dhall GI; Wyss R; Rodriquez la Puenta J; Andrade AT; Khan T; Kononova ES
    Contraception; 1990 Feb; 41(2):125-41. PubMed ID: 2107055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on the efficacy and acceptability of two contraceptive pills administered by the vaginal route: an international multicenter clinical trial.
    Coutinho EM; de Souza JC; da Silva AR; de Acosta OM; Alvarez F; Brache V; Garza Flores J; Vasquez-Estrada L; Santo R; Bassol S
    Clin Pharmacol Ther; 1993 Jan; 53(1):65-75. PubMed ID: 8422744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin patch and vaginal ring versus combined oral contraceptives for contraception.
    Lopez LM; Grimes DA; Gallo MF; Stockton LL; Schulz KF
    Cochrane Database Syst Rev; 2013 Apr; 2013(4):CD003552. PubMed ID: 23633314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.
    Chen JH; Wu SC; Shao WQ; Zou MH; Hu J; Cong L; Miao L; Wang C; Dong J; Gao J; Xiao BL
    Contraception; 1998 Jun; 57(6):371-9. PubMed ID: 9693396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.